Global Oligonucleotide Therapeutics Market

Download free Sample

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
In 2018, the global Oligonucleotide Therapeutics market size was 2255.5 million US$ and it is expected to reach 7906.8 million US$ by the end of 2025, with a CAGR of 16.7% during 2019-2025.

This report focuses on the global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oligonucleotide Therapeutics development in North America, Europe, South America, China and Japan.

The key players covered in this study

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

Market segment by Type, the product can be split into

Antisense Oligonucleotide
Aptamer
Other

In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.

Market segment by Application, split into

Neuromuscular Diseases
ATTR
Hepatic VOD
Other

According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.

Market segment by Regions/Countries, this report covers

North America
Europe
South America
China
Japan

The study objectives of this report are:

To analyze global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Oligonucleotide Therapeutics development in North America, Europe, South America, China and Japan.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Oligonucleotide Therapeutics are as follows:
History Year: 2014-2018

Base Year:

2018

Estimated Year:

2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.